

As the publishers of three important journals with distinct editorial missions and audiences within hepatology and its subspecialties, the American Association for the Study of Liver Diseases (AASLD) has the ability and expertise to quickly review and publish essential information on the current healthcare crisis posed by COVID-19 as it relates to liver disease and liver transplantation research.

The Editors-in-Chief of our three journals and their editorial teams are prepared to review and publish important information so that scientifically sound and compelling information will be available to medical providers as they brace for the surge in patients diagnosed with COVID-19. The need to communicate important discoveries to other researchers working on a problem of this magnitude was never greater.

AASLD journals will contribute to a free collection of COVID-19 on [Wiley Online Library](#). Wiley has joined an initiative of the US Office of Science and Technology Policy (OSTP) and publishers in 12 countries to make all their COVID-19 and coronavirus-related publications, and the available data supporting them, immediately accessible in PubMed Central and other appropriate public repositories, such as the COVID database of the World Health Organization. This material is licensed so as to be fully available for text and data mining and the application of machine learning techniques.

The types of manuscripts and necessary information for each type of manuscript is available for our journals by following these links: [Hepatology](#), [Liver Transplantation](#), [Hepatology Communications](#). However, because of the unique situation in which we find ourselves, all of our journals are especially interested in short reports – including single case reports - that we can review and publish quickly. Those manuscripts may contain up to 2000 words and they will receive an expedited peer review.

Please follow the following links to submit to our journals:

[Hepatology](#)

[Liver Transplantation](#)

[Hepatology Communications](#)

Our lodestar throughout this crisis will be to disseminate all credible discoveries in the area of COVID-19 as it impacts liver disease to all interested readers in whatever format that information requires and as quickly as possible. Throughout this crisis, our journals will not reduce their scientific standards, but we will increase our level of service to our authors and readers and the scientific and clinical communities.

Signed,

David Cohen

Paul Martin

Gyongyi Szabo